EU blocks merger of U.S. firms in cancer screening sector
Blocking the buyout of cancer-screening company GRAIL by biotech giant Illumina is a rare move by European regulators.
Blocking the buyout of cancer-screening company GRAIL by biotech giant Illumina is a rare move by European regulators.